In clinics, the anti-HER2 affibody molecule labelled with indium-111 for SPECT21 and gallium-68 for PET22 demonstrated ability to discriminate between breast cancer lesions with high and low receptor expression. This evidence concerns the gene ERBB2 and breast carcinoma.